Wealth Enhancement Advisory Services’s Esperion Therapeutics ESPR Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-10,000	Closed	-$4.2K	–	2642
2024 Q1	$4.2K	Buy	+10,000	New	+$24.3K	﹤0.01%	2435

Wealth Enhancement Advisory Services's ESPR Position: Q3 2026 in Review

Wealth Enhancement Advisory Services sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 12,321 shares — an estimated $39.2K sold.

Wealth Enhancement Advisory Services first reported a position in ESPR in Q1 2024 and held it in 8 quarters. The position peaked at $105K in Q4 2025. 0 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.

Wealth Enhancement Advisory Services reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
Wealth Enhancement Advisory Services sold 12,321 Esperion Therapeutics shares in Q3 2026, an estimated $39.2K.
Wealth Enhancement Advisory Services first reported a position in Esperion Therapeutics in Q1 2024 and held it in 8 quarters.
Wealth Enhancement Advisory Services's Esperion Therapeutics position peaked at $105K in Q4 2025.
0 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.